Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions

To evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention). To compare the clinical safety and efficacy by comparing net clinical events (defined as the combination of ischemic and hemorrhagic events) of the two DES used at 12 months after PCI.

NCT Number	NCT07190690
Lead Sponsor	Fundación EPIC
Conditions	Coronary Artery Disease
Enrollment	2,100 participants
Start Date	2025-12-19
Primary Completion	2029-10-15 (estimated)
Study Completion	2030-10-15 (estimated)
Updated on ClinicalTrials.gov	2026-08-10